Business Context and Reporting Period
Company: NextCure, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 10, 2025
Reporting Period: Event-specific report regarding a corporate action approved on July 10, 2025.
Key Financial Metrics
This filing is a current report regarding a corporate governance event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change announced is a one-for-twelve (1:12) reverse stock split of the Company's common stock. Key details include:
- Effective Date: Expected to become effective on July 14, 2025.
- Conversion Ratio: Every 12 shares of common stock issued and outstanding will be converted into one share.
- Fractional Shares: No fractional shares will be issued; stockholders will receive cash in lieu of fractional shares based on the closing price on the last trading day prior to the effective date.
- Adjustments: Proportionate adjustments will be made to outstanding equity awards, equity incentive plans, and exercise/conversion prices.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future performance, or specific risk factors beyond the mechanics of the reverse stock split. The event is intended to adjust the share structure and trading price.
Investor Verification Checklist
- Verify the exact effective time of the reverse stock split on July 14, 2025, to ensure proper trading on a split-adjusted basis.
- Confirm the cash payout calculation for any fractional shares held, based on the Nasdaq closing price on the last trading day prior to the effective date.
- Review the impact of the 1:12 split on the number of shares and exercise prices for any outstanding equity awards or options held.
- Monitor the post-split trading volume and price stability on the Nasdaq Global Select Market.